Therapeutics News and Research

RSS

Research offers potential for future treatment of childhood acute lymphoblastic leukemia

Researchers at Children's Hospital Los Angeles have discovered that by targeting a particular receptor, chemotherapy-resistant cancer cells can be killed in an acute form of childhood leukemia, offering the potential for a future treatment for patients who would otherwise experience relapse of their disease.

14 May 2014

Amakem commences Phase 2 dose-ranging study of AMA0076 drug for treatment of glaucoma

Amakem Therapeutics, a clinical stage ophthalmology company, today announced that first patients have commenced treatment in a Phase 2 dose-ranging study of its lead drug candidate, AMA0076 for the treatment of glaucoma.

13 May 2014

New study presents novel strategy for treating multiple myeloma

A new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) provides evidence that genetically modifying immune cells might effectively treat multiple myeloma, a disease that remains incurable and will account for an estimated 24,000 new cases and 11,100 deaths in 2014

13 May 2014

Research team identifies specific genes that may lead to improved survival of glioblastoma

A Henry Ford Hospital research team has identified specific genes that may lead to improved survival of glioblastoma, the most common and deadly form of cancerous brain tumor.

13 May 2014

Research may offer unique pathway for targeting new therapeutics for addiction treatment

A research team from the Friedman Brain Institute of the Icahn School of Medicine at Mount Sinai has published evidence that shows that subtle changes of inhibitory signaling in the reward pathway can change how animals respond to drugs such as cocaine.

13 May 2014

Abeona Therapeutics obtains FDA Orphan Drug Designations for Sanfilippo Syndrome therapies

Abeona Therapeutics, a start-up company created around intellectual property licensed from Nationwide Children's Hospital to develop treatments for Sanfilippo Syndrome Types A and B, has been granted Orphan Drug Designations for its lead investigational therapies by the U.S. Food and Drug Administration Office of Orphan Products Development.

12 May 2014

Akebia Therapeutics reports net loss of $9.7 million for Q1 2014

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced financial results for the first quarter ended March 31, 2014.

12 May 2014

Aratana initiates pivotal field effectiveness study for AT-001

Aratana Therapeutics, Inc., a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced the initiation of the pivotal field effectiveness study for AT-001 (grapiprant), the company's innovative drug for treating pain in dogs with osteoarthritis.

12 May 2014

Study of rare childhood neurodegenerative diseases identifies new source of DNA damage

St. Jude Children's Research Hospital scientists studying two rare, inherited childhood neurodegenerative disorders have identified a new, possibly common source of DNA damage that may play a role in other neurodegenerative diseases, cancer and aging.

12 May 2014

Ranbaxy to implement Instem's Provantis preclinical software suite at Gurgaon R&D center in India

Instem, a leading provider of IT solutions to the global early development healthcare market, is pleased to announce that Ranbaxy Laboratories Limited (Ranbaxy) has purchased the Provantis preclinical software suite to automate laboratory processes at their R&D Headquarters in Gurgaon, India.

9 May 2014

Neurovance reports positive results from EB-1020 SR phase 2a pilot study in adult ADHD patients

Neurovance, Inc. today announced complete results from its phase 2a pilot study of EB-1020 SR, a non-stimulant, in adult male patients with all subtypes of ADHD (attention deficit hyperactivity disorder).

8 May 2014

TSRI scientists create bacteria with expanded DNA code

Scientists at The Scripps Research Institute have engineered a bacterium whose genetic material includes an added pair of DNA “letters,” or bases, not found in nature. The cells of this unique bacterium can replicate the unnatural DNA bases more or less normally, for as long as the molecular building blocks are supplied.

8 May 2014

Scientists find 2 key proteins that regulate growth of mammary stem cells and contribute to breast cancer

By carefully controlling the levels of two proteins, researchers at the Salk Institute have discovered how to keep mammary stem cells-those that can form breast tissue-alive and functioning in the lab. The new ability to propagate mammary stem cells is allowing them to study both breast development and the formation of breast cancers.

8 May 2014

Ambrisentan cleared for use with phenprocoumon

Starting treatment with ambrisentan does not necessitate adjusting the dose of the oral anticoagulant phenprocoumon in patients with pulmonary hypertension who require both medications, report researchers.

7 May 2014

Targacept reports net loss of $11.6M in first quarter 2014

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the first quarter ended March 31, 2014.

7 May 2014

TGen/George Mason create strategic research alliance to benefit patients with cancer, life-threatening illnesses

The Translational Genomics Research Institute (TGen) and George Mason University today announced the creation of a strategic research alliance to benefit patients with cancer and other life-threatening illnesses.

7 May 2014

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

New data have been presented for the first time at the European Association of Dermato Oncology (EADO) Congress today on the investigational MEK inhibitor cobimetinib (GDC-0973) in combination with BRAFV600 inhibitor Zelboraf® (vemurafenib) for metastatic melanoma, the most aggressive form of skin cancer. The findings illustrate that cobimetinib and vemurafenib can be safely co-administered and that the combination shows promising anti-tumour activity, with a median progression-free survival (mPFS) of 13.7 months for BRAF inhibitor-naive patients.1

7 May 2014

Therapeutics News and Research

Research offers potential for future treatment of childhood acute lymphoblastic leukemia

Amakem commences Phase 2 dose-ranging study of AMA0076 drug for treatment of glaucoma

New study presents novel strategy for treating multiple myeloma

Research team identifies specific genes that may lead to improved survival of glioblastoma

Research may offer unique pathway for targeting new therapeutics for addiction treatment

Abeona Therapeutics obtains FDA Orphan Drug Designations for Sanfilippo Syndrome therapies

Akebia Therapeutics reports net loss of $9.7 million for Q1 2014

Aratana initiates pivotal field effectiveness study for AT-001

Study of rare childhood neurodegenerative diseases identifies new source of DNA damage

Ranbaxy to implement Instem's Provantis preclinical software suite at Gurgaon R&D center in India

Neurovance reports positive results from EB-1020 SR phase 2a pilot study in adult ADHD patients

TSRI scientists create bacteria with expanded DNA code

Scientists find 2 key proteins that regulate growth of mammary stem cells and contribute to breast cancer

Ambrisentan cleared for use with phenprocoumon

Targacept reports net loss of $11.6M in first quarter 2014

TGen/George Mason create strategic research alliance to benefit patients with cancer, life-threatening illnesses

New data presented at EADO on investigational MEK inhibitor in combination with BRAF inhibitor for metastatic melanoma

Novel bioinformatics approach suggests antimicrobial drug may help in treating advanced kidney cancer

ConvaTec posts strong financial results for FY 2013

Naurex's two lead antidepressant programs achieve major milestones

Next-generation therapeutics eBook eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News